VPC
DNLI icon

Vestal Point Capital’s Denali Therapeutics DNLI Stock Holding History

Vestal Point Capital’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34M Buy
1,773,326
+1,308,326
+281% +$26M 0.95% 38
2025
Q4 		$7.68M Buy
+465,000
New +$7.85M 0.26% 53
2024
Q3 		– Sell
-500,000
Closed -$11.6M – 74
2024
Q2 		$11.6M Buy
+500,000
New +$9.6M 0.87% 33

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vestal Point Capital's DNLI Position: Q1 2026 in Review

Vestal Point Capital increased its Denali Therapeutics (DNLI) stake by 281% in Q1 2026, buying an estimated $26M and bringing the position to 1,773,326 shares worth $34M. The position accounts for 0.95% of the portfolio, ranked #38.

Vestal Point Capital first reported a position in DNLI in Q2 2024 and has held it in 3 quarters since. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Vestal Point Capital held 1,773,326 shares of Denali Therapeutics worth $34M as of Q1 2026.
  • Vestal Point Capital bought 1,308,326 Denali Therapeutics shares in Q1 2026, an estimated $26M.
  • Denali Therapeutics made up 0.95% of Vestal Point Capital's portfolio in Q1 2026, its #38 holding.
  • Vestal Point Capital first reported a position in Denali Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.